Shopping Cart 0
Cart Subtotal
USD 0

NanoViricides Inc (NNVC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

NanoViricides Inc (NanoViricides), formerly Edot-com.com Inc is a biopharmaceutical company that provides nanomedicine technology solutions. The company conducts research in the areas of medical science and pharmaceutical technology such as polymeric micelles, multi-specific multi-targeting, anti-sense DNA, siRNA, ribozymes and gene therapy. It offers pipeline product portfolio such as drugs for various indications such as HIV, influenza, flaviviruses including dengue and eye drops, among others. The company develops drugs against various viral diseases including H5N1 bird flu, seasonal influenza, HIV, epidemic kerato-conjunctivitis, hepatitis C, rabies, dengue fever and Ebola virus, among others. NanoViricides is headquartered in Shelton, Connecticut, the US.

NanoViricides Inc (NNVC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

NanoViricides Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

NanoViricides Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

NanoViricides Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

NanoViricides Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

NanoViricides Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

NanoViricides Inc, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

NanoViricides Enters into Agreement with SUNY Upstate Medical University 10

NanoViricides Enters into Agreement with St. Jude Children's Research Hospital 11

NanoViricides Enters into Agreement with Baylor College of Medicine 12

NanoViricides Enters into Research Agreement with University of Pittsburgh 13

NanoViricides Expands into Agreement with University of Wisconsin-Madison 14

Equity Offering 15

NanoViricides Raises USD7.5 Million in Private Placement of Shares upon Exercise of Warrants 15

NanoViricides Completes Private Placement Of Units For USD 20 Million 16

NanoViricides Completes Public Offering Of Units For USD 10.3 Million 18

NanoViricides Completes Final Tranche Of Private Placement Of Series C Preferred Stock For USD 2.5 Million 19

NanoViricides Files Shelf Registration Statement For Public Offering Of Securities For USD 40 Million 21

Nanoviricides Completes Final Tranche Of Private Placement Of Series B Convertible Preferred Stock For USD 2.5 Million 22

Debt Offering 24

NanoViricides Completes Private Placement Of Debentures Due 2017 For USD 6 Million 24

NanoViricides Inc-Key Competitors 25

NanoViricides Inc-Key Employees 26

NanoViricides Inc-Locations And Subsidiaries 27

Head Office 27

Recent Developments 28

Financial Announcements 28

May 22, 2018: NanoViricides Files Quarterly Report for Period Ending March 31 2018 28

Feb 21, 2018: NanoViricides Files Quarterly Report for Period Ending December 31, 2017 30

Nov 20, 2017: NanoViricides Files Quarterly Report for Period Ending September 30, 2017 33

May 16, 2017: NanoViricides Files Quarterly Report for Period Ending 2017-03-31 34

Feb 16, 2017: NanoViricides Files Quarterly Report for Period Ending 2016-12-31 36

Corporate Communications 38

Jul 23, 2018: NanoViricides appoints Dr. Irach Taraporewala as the new CEO 38

Product News 39

11/06/2017: NanoViricides Provides Further Details on Its Herpes-Induced Acute Retinal Necrosis Animal Study to be Presented On November 10th at the Annual Meeting of the Ocular Microbiology and Immunology Group of the American Academy of Ophthalmology 39

06/06/2017: NanoViricides Reports Excellent Inhibitory Effects of Its Topical Shingles Treatment Candidates Against VZV in Multiple Cell Culture Studies 40

May 14, 2018: NanoViricides Provides Update, Says Company is Stable and is Moving Steadily towards Clinical Trials 41

Appendix 42

Methodology 42

About GlobalData 42

Contact Us 42

Disclaimer 42


List Of Figure

List of Figures

NanoViricides Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

NanoViricides Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

NanoViricides Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

NanoViricides Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

NanoViricides Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

NanoViricides Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

NanoViricides Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

NanoViricides Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

NanoViricides Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

NanoViricides Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

NanoViricides Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

NanoViricides Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

NanoViricides Inc, Deals By Therapy Area, 2012 to YTD 2018 8

NanoViricides Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

NanoViricides Enters into Agreement with SUNY Upstate Medical University 10

NanoViricides Enters into Agreement with St. Jude Children's Research Hospital 11

NanoViricides Enters into Agreement with Baylor College of Medicine 12

NanoViricides Enters into Research Agreement with University of Pittsburgh 13

NanoViricides Expands into Agreement with University of Wisconsin-Madison 14

NanoViricides Raises USD7.5 Million in Private Placement of Shares upon Exercise of Warrants 15

NanoViricides Completes Private Placement Of Units For USD 20 Million 16

NanoViricides Completes Public Offering Of Units For USD 10.3 Million 18

NanoViricides Completes Final Tranche Of Private Placement Of Series C Preferred Stock For USD 2.5 Million 19

NanoViricides Files Shelf Registration Statement For Public Offering Of Securities For USD 40 Million 21

Nanoviricides Completes Final Tranche Of Private Placement Of Series B Convertible Preferred Stock For USD 2.5 Million 22

NanoViricides Completes Private Placement Of Debentures Due 2017 For USD 6 Million 24

NanoViricides Inc, Key Competitors 25

NanoViricides Inc, Key Employees 26

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

NanoViricides Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.